Search Results
Your search for ,HOW matches 8288 pages
Showing 1601 - 1650Breast Cancer 2021–2022 Almanac
The past year has seen an unprecedented number of practice-changing advances across all three major breast cancer subtypes. For patients with early-stage triple-negative breast cancer, neoadjuvant chemotherapy plus pembrolizumab firmly entered the standard of care based on improvements in...
DESTINY-Breast04 Trial: T-DXd Significantly Improves Survival in Patients With HER2-Low Metastatic Breast Cancer
The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) doubled progression-free survival compared with chemotherapy alone in patients with “HER2-low” metastatic breast cancer—ie, patients with low levels of HER2 expression. The agent also extended overall survival for patients with low ...
Expert Point of View: Debu Tripathy, MD, and Hope S. Rugo, MD, FASCO
The ASCO Post asked Debu Tripathy, MD, Professor and Chair of Medical Breast Oncology at The University of Texas MD Anderson Cancer Center, Houston, and Hope S. Rugo, MD, FASCO, Professor of Medicine, Director of Breast Oncology and Clinical Trials Education at the University of California San...
Strides Are Being Made in the Treatment of Brain Metastases From Breast Cancer
New drugs for HER2-positive breast cancer are able to overcome some of the obstacles that have made brain metastases challenging to treat, according to Mark Pegram, MD, the Susy Yuan-Huey Hung Professor of Oncology at Stanford University School of Medicine in California, who described the promising ...
Aditya Bardia, MD, MPH, Comments on Findings From monarchE
The invited discussant of monarchE,1 Aditya Bardia, MD, MPH, Director, Breast Cancer Research, and Associate Professor of Medicine, Harvard Medical School, commented: “Based on a hazard ratio of 0.69 for invasive disease–free survival, the results are statistically significant and clinically...
Effect of Social Factors on Cancer Screening Rates Across U.S. Counties
Populations in U.S. counties defined as more vulnerable based on social factors—including socioeconomic status and racial and ethnic minority status—may be significantly less likely to receive timely breast, cervical, and colorectal cancer screenings, according to a recent study published by Bauer...
Qinjin Fan, PhD, on Equitable Lung Cancer Care and Mortgage Discrimination
Qinjin Fan, PhD, of the American Cancer Society, explores the question of how mortgage discrimination is linked to lower rates of guideline-concordant care for patients with non–small cell lung cancer. This study highlights the critical need to understand the pathways through which mortgage denials ...
Decrease in Breast Cancer Mortality Rate Continues, but Gap Persists for Black Women: From American Cancer Society Report
Although breast cancer death rates dropped by 43% from 1989 to 2020, Black women continue to be 40% more likely to die of the disease, despite a lower incidence, according to findings outlined in the American Cancer Society’s report Breast Cancer Statistics, 2022, and a companion study published by ...
ASCO Treatment Guidelines for HER2-Negative Metastatic Breast Cancer Updated to Reflect New Trastuzumab Deruxtecan Data
Just 1 month after the DESTINY-Breast04 data were presented at the 2022 ASCO Annual Meeting Plenary Session,1 an ASCO expert panel released updated guidance that endorses the adoption of the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) into clinical practice for patients with...
Cancer Care and Reproductive Health Resources for the Oncology Community
On June 24, 2022, the U.S. Supreme Court announced its decision in Dobbs v Jackson Women’s Health Organization, effectively eliminating the constitutional right to abortion and returning the power to regulate reproductive health to individual states. Some states have already taken action to...
Ibrutinib for Pediatric Patients With Chronic Graft-vs-Host Disease
On August 24, 2022, ibrutinib was approved for pediatric patients 1 year of age or older with chronic graft-vs-host disease after failure of one or more lines of systemic therapy.1 A new oral suspension formulation is available. Supporting Efficacy Data Approval was based on findings from the...
Mechanism Linking Air Pollution to Lung Cancer Identified
Although air pollution is associated with lung cancer, not much has been known about how one leads to the other. For the first time, researchers have identified a mechanism by which particulate matter in the air triggers non–small cell lung cancer (NSCLC) in people who have never smoked. Moreover,...
What Is the Best Induction Regimen for Newly Diagnosed PCNSL?
Primary central nervous system lymphoma (PCNSL) accounts for less than 1% of all non-Hodgkin lymphomas and between 3% and 4% of all brain tumors, with an age-adjusted incidence rate of four cases per million persons per year. Approximately 1,500 new cases are diagnosed each year in the United...
Cancer and Fertility Preservation: Will New Laws Leave Patients Without Options?
The legal climate surrounding reproductive health care and fertility preservation has changed drastically since the June 2022 Supreme Court decision to overturn Roe v Wade, which revoked the constitutional right to abortion. With this ruling, individual state legislatures are now able to pass laws...
Expert Point of View: Alexander M.M. Eggermont, MD; Omid Hamid, MD; and James Larkin, PhD
The results of SWOG S18011 were met with enthusiasm by attendees at the Presidential Symposium of the European Society for Medical Oncology (ESMO) Congress 2022. The ASCO Post captured the thoughts of several melanoma experts, who had somewhat different ideas about the immediate clinical...
The Development of Geriatric Oncology in France: An Outside View
With the aging of the world population, geriatric oncology is becoming a mainstay. Over the past year in The ASCO Post, we published a couple of articles on the history of oncology, including one on the history of geriatric oncology in the United States and Europe. Our goal was to promote a...
Darolutamide Combined With Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
On August 5, 2022, darolutamide was approved for use in combination with docetaxel for patients with metastatic hormone-sensitive prostate cancer.1 Approval was based on the double-blind ARASENS trial (ClinicalTrials.gov identifier NCT02799602), in which 1,305 patients were randomly assigned to...
Update on the Impact of the Russian Invasion of Ukraine on Patients With Cancer
In the more than 7 months since Russia invaded Ukraine on February 24, 2022, cancer care for Ukrainian citizens has changed dramatically. Ukraine was once a country able to provide its approximately 160,000 newly diagnosed patients with cancer each year with modern diagnostic methods, including...
Scott M. Welford, PhD, Named Sylvester’s Tumor Biology Research Program Co-Leader
Scott M. Welford, PhD, Professor and Biology Division Chief in Radiation Oncology at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, will lead the center’s Tumor Biology Research Program with Wael El-Rifai, MD, PhD, Associate Director of Basic Science at ...
COSMIC-313: Triplet Therapy Is Active in Renal Cell Carcinoma, but Toxicities Pose a Challenge
The addition of cabozantinib to nivolumab plus ipilimumab prolonged progression-free survival in untreated intermediate-risk patients with advanced renal cell carcinoma (RCC), according to the first results of the phase III COSMIC-313 trial. These findings were presented as a Presidential Symposium ...
Study Investigates Potential Embryonic Origin of Medulloblastomas
Medulloblastomas may exist in a premalignant form at birth after initially developing during the first or second trimester of pregnancy, according to a new international study published by Hendrikse et al in Nature. As medulloblastomas typically present around age 7, the team’s discovery is the...
Expert Point of View: Benjamin Besse, MD, PhD
Discussant of the IMpower010 abstract, Benjamin Besse, MD, PhD, Professor and Head of Clinical Research at Institute Gustave Roussy, Villejuif, France, said there is enough evidence to use adjuvant immunotherapy in stage II–IIIA resected non–small cell lung cancer (NSCLC), calling the increased...
Study Focuses on Molecular Details of Precancerous Clonal Outgrowth in Blood Cells
A common, spontaneous mutation in blood stem cells, which has been linked to a higher risk of blood cancer and cardiovascular disease, may promote these diseases by altering the stem cells’ programming of gene activity and the mix of blood cells they produce, according to a study co-led by...
Managing the Risk of Thrombosis in Polycythemia Vera
This is Part 1 of Updates in Myeloproliferative Neoplasms, a three-part video roundtable series. Stay tuned for future installments in the coming months. In this video, Dr. Prithviraj Bose and Dr. Ruben Mesa discuss how best to manage the risk of thrombosis in patients with polycythemia vera....
Genetic Variation May Explain Racial Disparity in Esophageal Cancer Cases
Esophageal adenocarcinoma is a type of cancer affecting the mucus-secreting glands of the lower esophagus and is the most common form of esophageal cancer. It is often preceded by Barrett’s metaplasia, a deleterious change in cells lining the esophagus. Though the cause of esophageal adenocarcinoma ...
First-Line Therapy in Metastatic Clear Cell RCC
This is Part 1 of Updates in Renal Cell Carcinoma, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Wenxin (Vincent) Xu, David Braun, and Bradley McGregor discuss first-line therapy in metastatic clear cell renal cell carcinoma...
Genomic Testing May Aid in Identifying Patients of African Descent With High-Risk Prostate Cancer
Black patients of African descent tend to be diagnosed more frequently with prostate cancer and have higher mortality rates than patients of other races and ethnicities. Despite this substantial disparity, few prospective studies focused on maximizing the recruitment of African American patients...
Can a Navigation Program Lower Care Costs for Patients With Cancer?
A cancer navigation program can reduce overall costs when deployed in collaboration with a statewide Medicare Advantage health plan across a wide range of practice types, according to findings to be presented by Worland et al at the upcoming 2022 ASCO Quality Care Symposium (Abstract 4). A...
Total Cost of Cancer Care May Be Reduced With Lower-Cost Alternate Drugs Without Compromising Quality of Care
Substituting biosimilars, generics, and clinically appropriate lower-cost drugs for established, costlier drugs was shown to be an effective way to reduce the total cost of care, by 5% or so, while maintaining the quality of care for patients with cancer. Even small shifts toward lower-cost drugs...
A Physicist Father Inspired a Love of Science in Oncology Researcher Stanton L. Gerson, MD
In this installment of the Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with Stanton (“Stan”) L. Gerson, MD, Dean and Senior Vice President for Medical Affairs, School of Medicine, and Acting Director of the Case Comprehensive Cancer Center and National Center for...
Changing the Algorithm for Relapsed or Refractory Large B-Cell Lymphomas
Despite a significant potential for cure, relapsed and refractory large B-cell lymphomas (LBCL) comprise the most common cause of lymphoma-related mortality. Sequential relapses reflect the limits of repeated exposure to chemotherapy, even when delivered at high doses. More than 30 years ago,...
Determining Prognosis in Aggressive Lymphomas: Integrating Liquid Biopsy Into Imaging Assessment
The incorporation of blood-based measurements—ie, “liquid biopsies”—into imaging assessment may refine the accuracy of prognosis in aggressive lymphomas, as described by David Kurtz, MD, PhD, Assistant Professor in the Division of Oncology, Stanford University Medical Center, in a talk at the 2022...
Patients With Multiple Myeloma May Face CAR T-Cell Shortages
From microchips to automobiles, people in the United States are experiencing shortages of all kinds of products, and oncology treatments are no exception. In particular, shortages related to chimeric antigen receptor (CAR) T-cell therapy have been reported, most acutely, for B-cell maturation...
Trastuzumab Deruxtecan for Advanced HER2-Mutant NSCLC
On August 11, 2022, fam-trastuzumab deruxtecan-nxki was granted accelerated approval for unresectable or metastatic non–small cell lung cancer (NSCLC) with tumors that have activating HER2 mutations, as detected by a U.S. Food and Drug Administration (FDA)-approved test and who have received a...
Capmatinib for Metastatic NSCLC With MET Exon 14 Skipping Mutation
On August 10, 2022, capmatinib was granted regular approval for patients with metastatic non–small cell lung cancer (NSCLC) with tumors having a mutation leading to mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by a U.S. Food and Drug Administration–approved test.1...
Expert Point of View: Benjamin Besse, MD, PhD
Discussant of the IMpower010 abstract, Benjamin Besse, MD, PhD, Professor and Head of Clinical Research at Institute Gustave Roussy, Villejuif, France, said there is enough evidence to use adjuvant immunotherapy in stage II–IIIA resected non–small cell lung cancer (NSCLC), calling the increased...
What the Supreme Court’s Abortion Decision Means for Patients With Cancer and Their Clinicians
On June 24, 2022, the Supreme Court ruled in Dobbs v Jackson Women’s Health Organization (Dobbs)1 and overturned Roe v Wade and Planned Parenthood v Casey, which recognized a federal constitutional right to end a pregnancy up to the point of viability. This decision opened the door for states to...
September 24 Is World Cancer Research Day
September 24 is World Cancer Research Day, an initiative organized by a collaboration of professional societies, research organizations, and other institutions. In advance of the event, the following declaration was published in order to outline the goals of the initiative: Cancer is projected to...
Precision Physical Activity Prescriptions May Improve Survival in Patients With Stage III Colon Cancer
Physical activity may be associated with improved outcomes for patients undergoing postoperative treatment for stage III colon cancer, according to findings from a new study out of Pennington Biomedical Research Center published by Brown et al in the Journal of Clinical Oncology. The study assessed ...
Housing Instability and Risk of Mortality in Patients With Cancer
Little is known about patients with cancer’s social welfare and how it affects their health outcomes. To address this, researchers at University of California (UC) San Diego School of Medicine and partnering institutions assessed the prevalence and impact of various social risk factors in patients...
Individuals of Mexican Descent May Have Higher Risk of Liver Cancer With Each Successive Generation
Studies show that Hispanic individuals have higher incidence rates of developing liver cancer and higher mortality rates—by 50% or more—than non-Hispanic White individuals for several cancers, including liver cancer. A new study investigating hepatocellular carcinoma among successive generations of ...
Prostate Tumor Biology May Be Influenced by Genetic Ancestry
Certain genetic variants found in prostate tumors of men of African descent were associated with African ancestry, according to two studies presented at the 15th American Association for Cancer Research (AACR) Conference on the Science of Cancer Health Disparities in Racial and Ethnic Minorities...
Neoadjuvant Endocrine Therapy May Elicit Differential Responses in Black vs White Women With Breast Cancer
Black women treated with neoadjuvant endocrine therapy for breast cancer were more likely to benefit than White women if treated at an earlier disease stage, but less likely to benefit than White women if treated at a later disease stage, according to results presented at the 15th American...
Many Families of Children With Leukemia May Experience Food Insecurity That Is Not Alleviated by Federal Assistance Program
Nearly one in four families of pediatric patients with acute lymphoblastic leukemia (ALL) enrolled in a clinical trial experienced food insecurity, and almost half of the families eligible for the Supplemental Nutrition Assistance Program (SNAP) did not receive benefits. In addition, receiving SNAP ...
Novel Photon-Counting CT May Improve Myeloma Bone Disease Detection
New computed tomography (CT) technology paired with artificial intelligence (AI)-based noise reduction may offer superior detection of bone disease associated with multiple myeloma at lower radiation doses than conventional CT, according to a recent study published by Baffour et al in Radiology....
Compliance of NCI-Designated Cancer Centers With January 2021 CMS Price Transparency Requirements
In a study reported in JAMA Surgery, Childers et al found that only one-third of hospitals with National Cancer Institute (NCI)-designated cancer center status were fully compliant with Centers for Medicare & Medicaid Services (CMS) price transparency requirements instituted in January 2021....
ASCO Applauds President Biden’s Leadership in Relaunching the Cancer Moonshot
On September 12, Lori J. Pierce, MD, FASTRO, FASCO, Board Chair of the Association for Clinical Oncology (ASCO), made the following statement: “President John F. Kennedy’s historic speech that inspired our nation and an entire generation of Americans to achieve manned space exploration underscored ...
Neoadjuvant Cemiplimab in Patients With Stage II to IV Cutaneous Squamous Cell Carcinoma
In an international, multicenter phase II clinical trial, 63.3% of patients with stage II to IV cutaneous squamous cell carcinoma saw their tumors nearly or completely eradicated when treated with the anti–PD-1 agent cemiplimab-rwlc before surgery. The results were presented by Gross et al at the...
Research Explores Multicancer Early Detection Blood Testing
Physicians, care providers, and payers may be preparing for a major shift in early cancer detection that will affect almost every stage of cancer diagnosis and treatment. New data supporting the accuracy of multicancer early detection blood testing, presented by Deb Schrag, MD, FASCO, MPH, at the...
PRESTO: Treatment Beyond Androgen-Deprivation Therapy for Relapsed Patients With High-Risk Prostate Cancer
Aggarwal et al presented data from PRESTO (AFT-19) at the European Society for Medical Oncology (ESMO) Congress 2022 (Abstract LBA63), the first trial to evaluate whether intensifying treatment beyond androgen-deprivation therapy (ADT) by adding apalutamide with or without abiraterone acetate plus...
